B cell dysregulation and depletion therapy in primary membranous nephropathy: Prospects and potential challenges

Int Immunopharmacol. 2024 Oct 25:140:112769. doi: 10.1016/j.intimp.2024.112769. Epub 2024 Aug 3.

Abstract

B cells are crucial to the humoral immune response, originating in the bone marrow and maturing in the spleen and lymph nodes. They primarily function to protect against a wide range of infections through the secretion of antibodies. The role of B cells in primary membranous nephropathy (PMN) has gained significant attention, especially following the discovery of various autoantibodies that target podocyte antigens and the observed positive outcomes from B cell depletion therapy. Increasing evidence points to the presence of abnormal B cell subsets and functions in MN. B cells have varied roles during the different stages of disease onset, progression, and relapse. Initially, B cells facilitate self-antigen presentation, activate effector T cells, and initiate cellular immunity. Subsequently, the disruption of both central and peripheral immune tolerance results in the emergence of autoreactive B cells, with strong germinal center responses as a major source of MN autoantibodies. Additionally, critical B cell subsets, including Bregs, memory B cells, and plasma cells, play roles in the immune dysregulation observed in MN, assisting in predicting disease recurrence and guiding management strategies for MN. This review offers a detailed overview of research advancements on B cells and elucidates their pathological roles in MN.

Keywords: B cell; Dysregulation; Primary membranous nephropathy; Therapy.

Publication types

  • Review

MeSH terms

  • Animals
  • Autoantibodies / immunology
  • B-Lymphocyte Subsets / immunology
  • B-Lymphocytes* / immunology
  • Glomerulonephritis, Membranous* / immunology
  • Glomerulonephritis, Membranous* / therapy
  • Humans
  • Lymphocyte Depletion*

Substances

  • Autoantibodies